Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13377382 | 0.79 | HSD17B10 (0.35) | MPO | |
| SCHEMBL21672490 | 0.77 | MPO (0.33) | MPO | |
| SCHEMBL25085439 | 0.73 | MPO (0.33) | MPO | |
| SCHEMBL20399887 | 0.70 | NLRP3 (0.31) | MPO | |
| SCHEMBL2054538 | 0.69 | MPO (0.42) | MPO | |
| SCHEMBL20939390 | 0.64 | MPO (0.38) | MPO | |
| SCHEMBL16920689 | 0.63 | MPO (0.47) | MPO | |
| SCHEMBL25768442 | 0.63 | HSD17B10 (0.50) | — | |
| SCHEMBL19782733 | 0.61 | KMT2A (0.33) | — | |
| SCHEMBL29777595 | 0.61 | MPO (0.46) | MPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348426-A1 | OXOPYRROLIDINE FPR2 AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230348426-A1 | OXOPYRROLIDINE FPR2 AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2023-11-02 | — | — | US | disclosed |
| US-11702428-B2 | Chemical compounds as inhibitors of interleukin-1 activity | GENENTECH, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| WO-2020102574-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
| WO-2020102096-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348426-A1 | OXOPYRROLIDINE FPR2 AGONISTS | FPR1, FPR2, FPR3 | MPO 460/4885 |
| US-11702428-B2 | Chemical compounds as inhibitors of interleukin-1 activity | IL1B, IL1A, IL18 | MPO 556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.